Moderna Earned a Decade's Revenue in Two Years. Then It Had to Build a Second Act From Scratch.

In 2022, Moderna booked $19.3 billion in total revenue and $8.4 billion in net income - more than $20 of diluted earnings for every share.¹ A company that had never sold a product before the pandemic had, in a single year, earned what a mature pharmaceutical franchise might earn across a decade. Then the world stopped lining up for shots. By 2024 revenue had fallen to $3.2 billion and the company posted a $3.6 billion net loss.² By 2025 it was down to roughly $1.9 billion - a further 40% drop - and still losing $2.8 billion a year.³ The vaccine that built the company was, by design, a one-time emergency.

The official story is that Moderna is a platform company diversifying into a broad pipeline, and the COVID revenue was always going to normalize. The harder reading: the windfall was not a runway into Act Two, it was a fortune the company has been spending while it searches for one. The cliff is real, the cash is finite, and the rescue bets have so far either underperformed or stalled.

Why a vaccine windfall doesn't become a foundation

A pandemic vaccine is the opposite of an annuity. Demand spikes precisely because a threat is acute and universal, and it collapses for the same reason - the threat recedes, the population is vaccinated, the urgency fades. Moderna's COVID franchise wasn't a growing subscription base; it was a global emergency that paid once and then receded into a thin, seasonal booster market. The money was real. The recurring revenue underneath it was not. So the only durable thing the windfall bought was time and cash to build a second business before the first one ran out - and that clock has been the real story since 2023.

The guidance that quietly disappeared

In January 2024, at the industry's flagship investor conference, Moderna told the market it expected about $4 billion in product sales that year, a return to organic sales growth in 2025, and a break-even point in 2026.⁴ None of it held. 2024 revenue came in at $3.2 billion, not the implied trajectory.² 2025 didn't grow - it fell 40%.³ And the 2026 break-even target has simply stopped appearing in the company's communications. This is the tell. When a company stops repeating a number, the number didn't get hit - it got buried.

The Act Two that sold $25 million

The first attempt at a second act was mRESVIA, approved by the FDA in May 2024 as the first mRNA RSV vaccine for adults 60 and over - a genuine scientific first.⁵ It was supposed to demonstrate that the platform could ship a non-COVID product into a real commercial market. It did not. In its season debut quarter it generated about $10 million against analyst expectations near $60 million, and finished its launch year at roughly $25 million in total sales.⁵ Against entrenched competitors and a contracting RSV market, the first mover in the technology was a distant also-ran in the category. The company's response was telling: it announced it would stop including launch-year product revenue in its financial framework at all.⁶ When you change the scoreboard rather than the score, you are managing the narrative, not the business.

The cancer bet, and the regulator who said not yet

With RSV stumbling, the entire diversification thesis has migrated to oncology - specifically intismeran autogene, an individualized neoantigen cancer vaccine partnered with Merck. The headline data are genuinely strong: the five-year follow-up of the Phase 2b KEYNOTE-942 melanoma study, reported in early 2026, showed a 49% reduction in the risk of recurrence or death when added to pembrolizumab in resected high-risk melanoma (HR 0.510).⁷ That is a serious clinical signal. But two facts puncture the bullish narrative. First, the FDA declined to grant accelerated approval on the strength of that Phase 2b data - even though the confirmatory Phase 3 melanoma trial was substantially enrolled.⁸ Second, the broader program has already shed a limb: the INTerpath-007 trial in cutaneous squamous cell carcinoma was quietly terminated after enrolling only 46 patients, with no Phase 3 to follow.⁸ The pivotal lung-cancer readouts that would actually move revenue are unlikely before 2030.⁸

Isn't this just normal biotech patience?

The fair objection is that this is how drug development always looks: a platform with a long pipeline, a genuinely promising lead asset, and a multi-year wait for pivotal data is the ordinary condition of a research-stage biotech - and Moderna still has billions in the bank to wait it out. There's truth in that, and the melanoma signal is real. But the steelman has a hole. Most biotechs in that position have never had a foundation product; Moderna had a $19 billion one and is now structurally a loss-making research company that happens to carry the residue of a blockbuster. It is burning cash against a clock, not raising it against a thesis. The honest counter to the counter is timing: a 49% Phase 2b signal the FDA won't fast-track, a terminated program, and pivotal data half a decade out do not bridge a revenue cliff that is happening now. The science may well arrive. The question is whether it arrives before the cash that the COVID windfall left behind runs thin.

Moderna proved that mRNA could be manufactured at planetary scale and sold for tens of billions of dollars in a single year. That was never in doubt again after 2022. What it has not yet proved is that the platform can produce a second product that anyone keeps buying once the emergency is over. The COVID vaccine didn't fail - it succeeded so completely that it left the company holding a fortune and a question. The fortune is being spent. The question - what Moderna sells when the world isn't afraid - is still open, and the most credible answer is parked behind a regulator who has already said: not on this evidence, not yet.